Tavneos
| Chemical Name | avacopan |
| Dosage Form | Capsule (oral; 10 mg) |
| Drug Class | Receptor antagonists |
| System | Immune |
| Company | ChemoCentryx |
| Approval Year | 2021 |
Indication
- Indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use